BIG DEAL: Aura Health Inc. Announces Second Tranche Of Its Subscription Receipt Offering And Share Exchange Transaction

MG
Minden Gross LLP

Contributor

Minden Gross LLP is a full service business law firm providing counsel in the broad areas of real estate, corporate/commercial transactions, litigation, securities and capital markets, and employment and labour law with global reach through Meritas Law Firms Worldwide. We also advise clients in personal matters related to tax and estate planning.
Aura Health Inc. is pleased to announce that it has closed the second tranche of its previously announced "best efforts" private placement subscription receipt offering for additional gross proceeds of $2,820,070.
Canada Food, Drugs, Healthcare, Life Sciences

Aura Health Inc. ("Aura") (CSE:BUZZ) is pleased to announce that it has closed the second tranche of its previously announced "best efforts" private placement subscription receipt offering (the "Offering") for additional gross proceeds of $2,820,070 (the "Second Tranche Offering"), as well as a share exchange transaction with FSD Pharma Inc. ("FSD"), a licensed producer under the Cannabis Act whereby, among other things, FSD issued $3 million of FSD shares (the "FSD Shares") to the Company in exchange for $3 million of Aura shares (the "Aura Shares"). Since the FSD Shares were issued to the Company on a private placement basis, the Company is in the process of finalizing an up to $3 million bridge facility (the "Bridge Facility") to cover the value of the FSD Shares until they are freely tradeable. The gross proceeds of $1,919,929 raised pursuant to the closing of the first tranche of the Offering, the gross proceeds of $2,820,070 raised pursuant to the Second Tranche Offering, the $3 million of FSD Shares issued to Aura in connection with the Share Exchange, and the Bridge Facility will generate $7,740,000 for the Company and will provide the Company with the funds required to close the proposed acquisition of an 80% equity interest in Pharmadrug Production GmbH, previously announced in a press release dated January 25, 2019.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More